Product Program year 2022 Source: CMS Open Payments

Daraprim

Drug Toxoplasmosis

NDC 69413-330-30

Open in the dashboard

General payments

$12,060

698 payments

Research payments

$0

0 payments

Through program year 2022, $12,060 in general payments and $0 in research payments were reported against Daraprim (Toxoplasmosis).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

3 rows
Year Kind Amount Payments
2022 General $2,419 129
2021 General $5,372 316
2020 General $4,268 253

Breakdown

Who paid General payments · program years 2020–2022
  1. Vyera Pharmaceuticals, LLC $12,060 698 payments
Top recipients General payments · program year 2022
  1. Carlos Bustamante Infectious Disease · Aventura, FL $50 2% · 2 payments
  2. Andres Rivero Infectious Disease · Hialeah, FL $50 2% · 2 payments
  3. Wayne Bonlie Family Medicine · Timonium, MD $49 2% · 2 payments
  4. Geoffrey Serfilippi Pulmonary Disease · Binghamton, NY $47 2% · 2 payments
  5. Jeffrey Greenhouse Critical Care Medicine · Binghamton, NY $47 2% · 2 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2022.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2022
  1. Infectious Disease Internal Medicine $975 40% · 46 practitioners
  2. Family Medicine $262 11% · 12 practitioners
  3. Internal Medicine $233 10% · 13 practitioners
  4. Ophthalmology $208 9% · 11 practitioners
  5. Nurse Practitioner $115 5% · 6 practitioners

The top 5 of 19 specialties; each share is of general payments naming this product to practitioners with a specialty in 2022. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2022
  1. California $362 15% · 20 recipients
  2. Virginia $263 11% · 11 recipients
  3. New York $209 9% · 7 recipients
  4. Texas $185 8% · 11 recipients
  5. Florida $178 7% · 6 recipients

The top 5 of 25 states; each share is of general payments naming this product in 2022 where a state was reported.

The top 25 states, free in the app

698 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record